How one share can change your life, page-2

Been moments of uncertainty over the last few weeks, then I keep reading this....


The SMARTCOUGH-C-2 study is a revision of ResApp’s earlier SMARTCOUGH-C study with significant improvements made to training and processes. Improvements in hospital staff training and an improved audio recording application has produced higher quality cough audio data in the SMARTCOUGH-C-2 study, subsequently verified by a rigorous quality assurance process which found to date that less than 3% of recordings were unacceptable. An independent, centralised clinical adjudication panel and less subjective clinical case definitions are also being used to ensure consistent clinical diagnosis.

“We are grateful once again to all the patients who participated in the revised study, as well as the investigators and their teams for their hard work and considerable skill that have made this study possible,“ said Tony Keating, CEO and Managing Director of ResApp. “With higher quality audio data throughout the study, and a consistent, less subjective clinical adjudication process we are confident that we have mitigated the issues that we identified in our earlier SMARTCOUGH-C study. We now look forward to receiving top-line results which will form the basis of our de novo premarket submission for ResAppDx in the United States.

• Significant improvements to training and process
• Improved audio recording
• Higher quality cough audio data
• Verified by rigorous QA process
• Less than 3% unacceptable
• Independent centralised clinical adjudication panel
• Less subjective clinical case definitions
• We’re confident that we have mitigated the issues identified in earlier study

There’s clear indications to expect outstanding results....we wait.